Cellares Stock

Cellares, a biotechnology innovator headquartered in South San Francisco, was founded to address the inefficiencies and high costs associated with traditional cell therapy manufacturing. The company introduced the first Integrated Development and Manufacturing Organization (IDMO) model, which integrates advanced technology with manufacturing services to streamline and scale up the production of cell therapies. The centerpiece of Cellares’ innovation is the Cell Shuttle™, a modular, fully automated, and closed platform designed for industrial-scale cell therapy production. This system offers up to a tenfold increase in productivity and a significant reduction in manufacturing costs, positioning it as a revolutionary solution in the field. The Cell Shuttle™ operates in a cGMP-compliant environment, ensuring high-quality standards throughout the production process. Cellares also offers other cutting-edge technologies, including the Consumable Cartridge, which facilitates single-use automation, and the Cell Q™, an automated high-throughput platform designed for stringent quality control. These technologies collectively enable biopharmaceutical companies to accelerate the development and delivery of life-saving cell therapies, making treatments more accessible to patients worldwide. Cellares' approach reduces the complexities of cell therapy manufacturing, addressing the bottlenecks that have historically limited the scalability and affordability of these therapies. The company's mission is to democratize access to cell therapies by making the manufacturing process more efficient, reliable, and cost-effective. As part of its growth strategy, Cellares is expanding its global footprint with the establishment of "Smart Factories," which are designed to provide flexible and scalable production capabilities. These facilities will further enhance the ability of the industry to meet the growing demand for cell therapies, positioning Cellares at the forefront of a critical transformation in healthcare manufacturing.